Overview

A Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects With Active Rheumatoid Arthritis Receiving Background Methotrexate

Status:
Completed

Trial end date:
2012-05-28

Target enrollment:

Participant gender:

Summary

This was a Phase II, randomized, open-label, multicenter study designed to evaluate the immune response to vaccines after administration of 1000 mg of rituximab in subjects with active rheumatoid arthritis (RA) who were receiving background methotrexate (MTX).

Phase:

Phase 2

Details

Lead Sponsor:

Genentech, Inc.

Treatments:

Heptavalent Pneumococcal Conjugate Vaccine
Keyhole-limpet hemocyanin
Methotrexate
Rituximab
Vaccines